Liposomes and antibodies

Combined immunotherapy significantly increases survival in liver cancer

Svetlana Maslova, Hi-tech+

Together, the two drugs work much more effectively than separately. Scientists have shown that the new treatment strategy can achieve impressive results in slowing the progression of the disease, stimulating immune cells against cancer, as well as increasing life expectancy.

Scientists from the University of Missouri presented the results of preclinical studies that found a specific combination of immunotherapy against liver tumors.

Article by Qi et al. Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer published in The FASEB Journal – VM.

Today, the average five-year survival rate is about 20%, so more effective treatment strategies are in high demand.

Experiments on mouse models have shown that the tumor-suppressing lipid molecule of the LipC6 nanoliposome and the CTLA4 antibody, when used together, significantly slow down tumor growth and increase the activity of T cells attacking the tumor. Scientists also noted a noticeable increase in the life expectancy of rodents.

It is noteworthy that such high efficiency was observed only for this combination of drugs. Other combinations have not shown significant benefits. In further research, scientists have yet to understand the mechanism that provides such a therapeutic result.

Given that both drugs have already been approved for humans, this protocol of combined treatment may soon be translated into clinical practice.

Another promising cancer treatment strategy, including advanced cases with metastases, uses oncolytic viruses. It is already being tested in clinical trials in patients with colon, lung, breast, ovarian and pancreatic cancers.

Portal "Eternal youth" http://vechnayamolodost.ru